NRX Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $8 |
Gross Profit | -1 | -1 | ||
EBITDA | -9,077 | -1,621 | -7,047 | -6,297 |
EBIT | -9,078 | -1,623 | -7,048 | -6,298 |
Net Income | -9,078 | -1,623 | -7,897 | -6,528 |
Net Change In Cash | 0 | 0 | 0 | 8 |
Free Cash Flow | -2,098 | -2,306 | -3,505 | -3,671 |
Cash | 1,443 | 1,646 | 1,898 | 1,319 |
Basic Shares | 10,517 | 10,973 | 10,517 | 8,852 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -5 | -4 | -2 | |
EBITDA | -18,502 | -30,025 | -39,750 | -93,043 |
EBIT | -30,030 | -39,754 | -93,045 | |
Net Income | -25,126 | -30,150 | -35,235 | -71,715 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,637 | -21,660 | -39,765 | -37,710 |
Cash | 1,443 | 4,595 | 20,054 | 27,605 |
Basic Shares | 10,517 | 7,576 | 65,766 | 46,917 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.77 |
2024-09-30 | -$0.15 |
2024-06-30 | -$0.67 |
2024-03-31 | -$0.74 |
